HANGZHOU, China, Nov. 14, 2018 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider in China, today announced its financial results for its second fiscal quarter, ended September 30, 2018.
Mr. Lei Liu, Chief Executive Officer and Chairman of Jo-Jo Drugstores, commented, "We are pleased to report our financial results for the second quarter of our 2019 fiscal year. Our revenue grew 16.7% compared to the same period of the previous year as we continued to grow our retail drugstore and wholesale businesses. In the coming quarters we are excited to attempt to improve our online offerings, improve online/offline integration and continue to refine our customer experience with more medical care services. Our recent proactive steps to achieve these aims include the addition of Mr. Wei Hu to our management team as Chief Operating Officer, a veteran of the healthcare industry and strong executor, as we attempt to differentiate ourselves in the new retail pharmacy landscape."
Second Quarter of Fiscal 2019 Financial Highlights
For the Three Months Ended September 30, |
||||||
($ millions, except per share data) |
2018 |
2017 |
% Change |
|||
Revenues |
27.41 |
23.49 |
16.7% |
|||
Retail drugstores |
18.14 |
15.05 |
20.5% |
|||
Online pharmacy |
2.12 |
3.07 |
-30.7% |
|||
Wholesale |
7.15 |
5.38 |
32.9% |
|||
Gross profit |
5.80 |
5.56 |
4.3% |
|||
Gross margin |
21.2% |
23.7% |
-2.5 pp* |
|||
Loss from operations |
(1.64) |
(1.65) |
-0.4% |
|||
Net loss |
(1.60) |
(1.17) |
37.1% |
|||
Loss per share |
(0.06) |
(0.05) |
20.0% |
|||
*Notes: pp represents percentage points |
||||||
Second Quarter of Fiscal 2019 Financial Results
Revenue
Revenue for the three months ended September 30, 2018 increased by $3.92 million, or 16.7%, to $27.41 million from $23.49 million for the same period of last year. The increase in revenue was primarily due to the increase in retail drugstores and wholesale businesses, partially offset by the decrease in online pharmacy business.
For the Three Months Ended September 30, |
||||||||||||
2018 |
2017 |
|||||||||||
($ millions) |
Revenues |
Cost of Goods Sold |
Gross Margin |
Revenues |
Cost of Goods Sold |
Gross Margin |
||||||
Retail drugstores |
18.14 |
13.28 |
26.8% |
15.05 |
10.80 |
28.2% |
||||||
Online pharmacy |
2.12 |
1.91 |
10.1% |
3.07 |
2.67 |
13.0% |
||||||
Wholesale |
7.15 |
6.42 |
10.1% |
5.38 |
4.46 |
17.0% |
||||||
Total |
27.41 |
21.61 |
21.2% |
23.49 |
17.93 |
23.7% |
||||||
Revenue from the retail drugstores business increased by $3.09 million, or 20.5%, to $18.14 million for the three months ended September 30, 2018 from $15.05 million for the same period of last year. The increase was primarily due to consumer-facing benefits such as emphasis on onsite medical care, chronic disease management services, incremental DTP (Direct-to-Patient) business caused by continuous hospital medical reform, promotional campaigns such as our fifteen-year anniversary sales, and maturing of stores opened a year ago.
Revenue from the online pharmacy business decreased by $0.94 million, or 30.7%, to $2.12 million for the three months ended September 30, 2018 from $3.07 million for the same period of last year. The decrease was mainly caused by a decline in our sales via e-commerce platforms which suspended OTC drug sales on their sites directly, offset by the increase in business referred from Pharmacy Benefit Management ("PBM") providers. The Company is adding more non-medical health products such as nutritional supplements to its inventory to counteract the decline in sales of the OTC drug category.
Revenue from the wholesale business increased by $1.77 million, or 32.9%, to $7.15 million for the three months ended September 30, 2018 from $5.38 million for the same period of last year. The increase was primarily due to sale of certain medicines, which the Company sold in large quantity at its retail stores, to other vendors at competitive prices, as well as the sale of certain nutritional supplements as sales agents.
Gross profit and gross margin
Total cost of goods sold increased by $3.68 million, or 20.5%, to $21.61 million for the three months ended September 30, 2018 from $17.93 million for the same period last year. Gross profit increased by $0.24 million, or 4.3%, to $5.80 million for three months ended September 30, 2018 from $5.56 million for the same period last year. Overall gross margin decreased by 2.5 percentage points to 21.2% for the three months ended September 30, 2018, from 23.7% for the same period of last year, due to lower profit margin in retail and online pharmacy sales.
Gross margin for retail drugstores decreased by 1.4 percentage points to 26.8% for the three months ended September 30, 2018, from 28.2% for the same period of last year, due to promotion campaigns, such as the Company's fifteenth anniversary celebration, and government price restrictions on certain drugs sales reimbursed by the government medical insurance program.
Gross margin for the online pharmacy decreased by 2.9 percentage points to 10.1% for the three months ended September 30, 2018, from 13.0% for the same period of last year, due to intense competition in the online pharmacy industry.
Gross margin for wholesale decreased by 6.9 percentage points to 10.1% for the three months ended September 30, 2018, from 17.0% for the same period of last year, primarily as a result of different product demand by certain pharmaceutical vendors.
Loss from operations
Selling and marketing expenses increased by $0.87 million, or 20.1%, to $5.22 million for the three months ended September 30, 2018 from $4.35 million for the same period of last year. The increase in selling and marketing expenses was primarily related to store expansion, offset by decline in expense of wholesale business.
General and administrative expenses decreased by $0.64 million, or 22.4%, to $2.22 million for the three months ended September 30, 2018 from $2.86 million for the same period of last year. The decrease in general and administrative expenses was primarily caused by a decrease in additional bad debt expense.
Loss from operations was $1.64 million for the three months ended September 30, 2018, compared to $1.65 million for the same period of last year. Operating margin was negative 6.0% for the three months ended September 30, 2018, compared to negative 7.0% for the same period of last year.
Net loss
Net loss was $1.60 million, or $0.06 per basic and diluted share for the three months ended September 30, 2018, compared to $1.17 million, or $0.05 per basic and diluted share for the same period of last year.
Six Months Ended September 30, 2018 Financial Highlights
For the Six Months Ended September 30, |
||||||
($ millions, except per share data) |
2018 |
2017 |
% Change |
|||
Revenues |
50.18 |
45.16 |
11.1% |
|||
Retail drugstores |
34.10 |
28.07 |
21.5% |
|||
Online pharmacy |
4.14 |
6.20 |
-33.2% |
|||
Wholesale |
11.93 |
10.89 |
9.5% |
|||
Gross profit |
11.41 |
9.74 |
17.2% |
|||
Gross margin |
22.7% |
21.6% |
1.1 pp* |
|||
Loss from operations |
(2.21) |
(3.11) |
-29.1% |
|||
Net loss |
(2.30) |
(2.59) |
-11.2% |
|||
Loss per share |
(0.08) |
(0.10) |
-22.6% |
|||
*Notes: pp represents percentage points |
||||||
Six Months Ended September 30, 2018 Financial Results
Revenue
Revenue for the six months ended September 30, 2018 increased by $5.02 million, or 11.1%, to $50.18 million from $45.16 million for the same period of last year. The increase in revenue was primarily due to the increase in retail drugstores and wholesale business, partially offset by the decrease in online pharmacy business.
For the Six Months Ended September 30, |
||||||||||||
2018 |
2017 |
|||||||||||
($ millions) |
Revenues |
Cost of Goods Sold |
Gross Margin |
Revenues |
Cost of Goods Sold |
Gross Margin |
||||||
Retail drugstores |
34.10 |
24.44 |
28.3% |
28.07 |
20.54 |
26.8% |
||||||
Online pharmacy |
4.14 |
3.65 |
11.9% |
6.20 |
5.51 |
11.1% |
||||||
Wholesale |
11.93 |
10.68 |
10.5% |
10.89 |
9.38 |
13.9% |
||||||
Total |
50.18 |
38.77 |
22.7% |
45.16 |
35.43 |
21.6% |
||||||
Revenue from the retail drugstores business increased by $6.04 million, or 21.5%, to $34.10 million for the six months ended September 30, 2018 from $28.07 million for the same period of last year. The increase was primarily due to consumer-facing benefits such as emphasis on onsite medical care, chronic disease management, incremental DTP (Direct-to-Patient) business caused by continuous hospital medical reform, and maturing of stores opened a year ago.
Revenue from the online pharmacy business decreased by $2.06 million, or 33.2%, to $4.14 million for the six months ended September 30, 2018, from $6.20 million for the same period of last year. The decrease was mainly caused by a decline in our sales via e-commerce platforms which suspended the sale of OTC drugs on their sites directly, offset by the increase in business referred from PBM providers. The Company is adding more non-medical health products such as nutritional supplements to its inventory to counteract the decline in sales of OTC drug category.
Revenue from the wholesale business increased by $1.04 million, or 9.5%, to $11.93 million for the six months ended September 30, 2018 from $10.89 million for the same period of last year. The increase was primarily a result of the Company's ability to sell certain medicines, which the Company sold in large quantity at its retail stores, to other vendors at competitive prices, as well as the sale of certain nutritional supplements as sales agents.
Gross profit and gross margin
Total cost of goods sold increased by $3.34 million, or 9.4%, to $38.77 million for the six months ended September 30, 2018 from $35.43 million for the same period of last year. Gross profit increased by $1.68 million, or 17.2%, to $11.41 million for six months ended September 30, 2018 from $9.74 million for the same period of last year. Overall gross margin increased by 1.1 percentage points to 22.7% for the six months ended September 30, 2018, from 21.6% for the same period of last year, due to higher retail profit margins.
Gross margin for retail drugstores increased by 1.5 percentage points to 28.3% for the six months ended September 30, 2018, from 26.8% for the same period of last year, primarily because of corporate operational strategy adjustments to focus on high profit margin products, introducing new suppliers, and renegotiating prices with suppliers periodically.
Gross margin for online pharmacy increased by 0.8 percentage points to 11.9% for the six months ended September 30, 2018, from 11.1% for the same period of last year. The increase was due to the increase in sales via the Company's own official website, as well as the decrease in sales via third-party platforms, which are usually subject to low profit margins.
Gross margin for wholesale decreased by 3.4 percentage points to 10.5% for the six months ended September 30, 2018, from 13.9% for the same period of last year, primarily a result of different products the Company carried and sold to certain pharmaceutical vendors.
Loss from operations
Selling and marketing expenses increased by $1.58 million, or 19.1%, to $9.85 million for the six months ended September 30, 2018 from $8.27 million for the same period of last year. The increase in selling and marketing expenses was primarily due to store expansion, offset by decline in expense of wholesale business.
General and administrative expenses decreased by $0.81 million, or 17.7%, to $3.77 million for the six months ended September 30, 2018 from $4.58 million for the same period of last year. The decrease in general and administrative expenses was primarily caused by a decrease in additional bad debt expense.
Loss from operations was $2.21 million for the six months ended September 30, 2018, compared to $3.11 million for the same period of last year. Operating margin was negative 4.4% for the six months ended September 30, 2018, compared to negative 6.9% for the same period of last year.
Net loss
Net loss was $2.30 million, or $0.08 per basic and diluted share for the six months ended September 30, 2018, compared to $2.59 million, or $0.10 per basic and diluted share for the same period of last year.
Financial Condition
As of September 30, 2018, the Company had cash of $6.92 million, compared to $15.13 million as of March 31, 2018. Net cash used in operating activities was $2.92 million for the six months ended September 30, 2018, compared to $0.52 million for the same period of last year. Net cash used in investing activities was $0.39 million for the six months ended September 30, 2018, compared to $1.10 million for the same period of last year. Net cash used in financing activities was $4.14 million for the six months ended September 30, 2018, compared to $0.86 million for the same period of last year.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in China. Jo-Jo Drugstores currently operates retail drugstores and an online pharmacy. It is also a wholesale distributor of products similar to those carried in its pharmacies and it cultivates herbs used for traditional Chinese medicine. For more information about the Company, please visit http://www.chinajojodrugstores.com/. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Chief Financial Officer
+86-571-88077108
frank.zhao@jojodrugstores.com
Steve Liu
Investor Relations Director
steve.liu@jojodrugstores.com
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-917-609-0333
tina.xiao@ascent-ir.com
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||
September 30, |
March 31, |
||||
2018 |
2018 |
||||
ASSETS |
|||||
CURRENT ASSETS |
|||||
Cash |
$ |
6,922,357 |
$ |
15,132,640 |
|
Restricted cash |
16,786,612 |
16,319,551 |
|||
Financial assets available for sale |
162,224 |
175,140 |
|||
Notes receivable |
223,954 |
279,082 |
|||
Trade accounts receivable |
7,830,713 |
8,322,393 |
|||
Inventories |
13,799,438 |
13,429,568 |
|||
Other receivables, net |
3,826,619 |
3,098,079 |
|||
Advances to suppliers |
3,234,939 |
3,447,452 |
|||
Other current assets |
1,484,108 |
2,116,237 |
|||
Total current assets |
54,270,964 |
62,320,142 |
|||
PROPERTY AND EQUIPMENT, net |
2,538,901 |
2,843,640 |
|||
OTHER ASSETS |
|||||
Long-term investment |
42,268 |
40,890 |
|||
Farmland assets |
734,951 |
796,286 |
|||
Long term deposits |
2,269,241 |
2,501,968 |
|||
Other noncurrent assets |
1,279,651 |
1,253,352 |
|||
Intangible assets, net |
3,567,044 |
4,056,414 |
|||
Total other assets |
7,893,155 |
8,648,910 |
|||
Total assets |
$ |
64,703,020 |
$ |
73,812,692 |
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||
CURRENT LIABILITIES |
|||||
Accounts payable, trade |
22,513,388 |
25,259,526 |
|||
Notes payable |
15,509,129 |
19,180,200 |
|||
Other payables |
4,823,881 |
4,272,523 |
|||
Other payables - related parties |
726,670 |
850,342 |
|||
Customer deposits |
4,435,964 |
4,040,867 |
|||
Taxes payable |
91,613 |
366,040 |
|||
Accrued liabilities |
1,108,740 |
841,993 |
|||
Total current liabilities |
49,209,385 |
54,811,491 |
|||
Purchase option and warrants liability |
227,635 |
138,796 |
|||
Total liabilities |
49,437,020 |
54,950,287 |
|||
COMMITMENTS AND CONTINGENCIES |
|||||
STOCKHOLDERS' EQUITY |
|||||
Common stock; $0.001 par value; 250,000,000 shares authorized; 28,936,778 and 28,936,778 shares issued and outstanding as of September 30, 2018 and March 31, 2018 |
28,937 |
28,937 |
|||
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of September 30, 2018 and March 31, 2018 |
- |
- |
|||
Additional paid-in capital |
43,697,909 |
43,599,089 |
|||
Statutory reserves |
1,309,109 |
1,309,109 |
|||
Accumulated deficit |
(31,894,456) |
(29,661,190) |
|||
Accumulated other comprehensive income |
2,759,433 |
3,586,460 |
|||
Total stockholders' equity |
15,900,932 |
18,862,405 |
|||
Noncontrolling interests |
(634,932) |
- |
|||
Total equity |
15,266,000 |
18,862,405 |
|||
Total liabilities and stockholders' equity |
$ |
64,703,020 |
$ |
73,812,692 |
|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) |
|||||||||||||
For the three months ended |
For the six months ended |
||||||||||||
2018 |
2017 |
2018 |
2017 |
||||||||||
REVENUES, NET |
$ |
27,409,046 |
$ |
23,491,043 |
$ |
50,181,612 |
$ |
45,161,411 |
|||||
COST OF GOODS SOLD |
21,611,945 |
17,933,446 |
38,767,708 |
35,426,153 |
|||||||||
GROSS PROFIT |
5,797,101 |
5,557,597 |
11,413,904 |
9,735,258 |
|||||||||
SELLING EXPENSES |
5,223,523 |
4,350,772 |
9,850,501 |
8,267,631 |
|||||||||
GENERAL AND ADMINISTRATIVE EXPENSES |
2,215,484 |
2,855,555 |
3,770,012 |
4,580,998 |
|||||||||
TOTAL OPERATING EXPENSES |
7,439,007 |
7,206,327 |
13,620,513 |
12,848,629 |
|||||||||
(LOSS) FROM OPERATIONS |
(1,641,906) |
(1,648,730) |
(2,206,609) |
(3,113,371) |
|||||||||
INTEREST INCOME |
26,060 |
358,344 |
73,232 |
403,243 |
|||||||||
OTHER INCOME(LOSS), NET |
94,582 |
(8,703) |
(20,359) |
(38,051) |
|||||||||
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES |
(81,866) |
148,427 |
(88,840) |
198,751 |
|||||||||
(LOSS) BEFORE INCOME TAXES |
(1,603,130) |
(1,150,662) |
(2,242,576) |
(2,549,428) |
|||||||||
PROVISION FOR INCOME TAXES |
(415) |
18,047 |
56,754 |
38,585 |
|||||||||
NET (LOSS) |
(1,602,715) |
(1,168,709) |
(2,299,330) |
(2,588,013) |
|||||||||
OTHER COMPREHENSIVE (LOSS) INCOME |
|||||||||||||
Foreign currency translation adjustments |
(1,448,661) |
633,184 |
(827,027) |
1,092,253 |
|||||||||
COMPREHENSIVE (LOSS) |
$ |
(3,051,376) |
$ |
(535,525) |
$ |
(3,126,357) |
$ |
(1,495,760) |
|||||
WEIGHTED AVERAGE NUMBER OF SHARES: |
|||||||||||||
Basic |
28,936,778 |
25,214,678 |
28,936,778 |
25,214,678 |
|||||||||
Diluted |
28,936,778 |
25,214,678 |
28,936,778 |
25,214,678 |
|||||||||
EARNINGS PER SHARES: |
|||||||||||||
Basic |
$ |
(0.06) |
$ |
(0.05) |
$ |
(0.08) |
$ |
(0.10) |
|||||
Diluted |
$ |
(0.06) |
$ |
(0.05) |
$ |
(0.08) |
$ |
(0.10) |
|||||
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||
Six months ended |
||||||
2018 |
2017 |
|||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||
Net loss |
$ |
(2,299,330) |
$ |
(2,588,013) |
||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||
Bad debt direct write-off and provision |
890,576 |
1,241,159 |
||||
Depreciation and amortization |
557,930 |
590,618 |
||||
Stock based compensation |
71,427 |
689,372 |
||||
Change in fair value of purchase option derivative liability |
88,840 |
(198,751) |
||||
Accounts receivable, trade |
(833,992) |
(2,138,968) |
||||
Notes receivable |
32,528 |
(49,387) |
||||
Inventories and biological assets |
(1,587,645) |
(789,355) |
||||
Other receivables |
(800,686) |
(39,756) |
||||
Advances to suppliers |
(611,849) |
958,032 |
||||
Other current assets |
469,985 |
(180,048) |
||||
Long term deposit |
18,851 |
(813,282) |
||||
Other noncurrent assets |
(139,597) |
(106,981) |
||||
Accounts payable, trade |
(603,967) |
2,911,679 |
||||
Other payables and accrued liabilities |
1,305,221 |
(181,932) |
||||
Customer deposits |
773,748 |
308,252 |
||||
Taxes payable |
(253,496) |
(133,285) |
||||
Net cash used in operating activities |
(2,921,456) |
(520,646) |
||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||
Disposal of financial assets available for sale |
88,897 |
(73,915) |
||||
Purchase of financial assets available for sale |
(91,099) |
- |
||||
Acquisition of equipment |
(142,681) |
(212,358) |
||||
Increase in construction-in-progress |
- |
(473,716) |
||||
Increase intangible assets |
- |
(298,617) |
||||
Investment in a joint venture |
- |
(9,387) |
||||
Additions to leasehold improvements |
(244,047) |
(27,986) |
||||
Net cash used in investing activities |
(388,930) |
(1,095,979) |
||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||
Change in restricted cash |
(1,947,655) |
(503,908) |
||||
Proceeds from notes payable |
16,177,514 |
12,664,216 |
||||
Repayment of notes payable |
(18,290,325) |
(12,929,115) |
||||
Proceeds from equity and debt financing |
7,667 |
- |
||||
Repayment of other payables-related parties |
(84,543) |
(88,698) |
||||
Net cash used in financing activities |
(4,137,342) |
(857,505) |
||||
EFFECT OF EXCHANGE RATE ON CASH |
(762,555) |
947,579 |
||||
INCREASE IN CASH |
(8,210,283) |
(1,526,551) |
||||
CASH, beginning of year |
15,132,640 |
18,364,424 |
||||
CASH, end of year |
$ |
6,922,357 |
$ |
16,837,873 |
||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
||||||
Cash paid for income taxes |
$ |
57,460 |
$ |
42,689 |
||
View original content:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-reports-second-quarter-2019-financial-results-300749314.html
